Kevindol (Ketorolac Trometamol)

Ketorolac trometamol works by non‑selectively inhibiting the cyclooxygenase enzymes COX‑1 and COX‑2. This inhibition blocks the synthesis of prostaglandins, which are mediators of inflammation, pain, and fever, thereby providing potent analgesic and anti‑inflammatory effects.

The specific dose of Kevindol is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and route of administration. Healthcare professionals follow local guidelines and adjust the regimen to achieve effective pain control while minimising risk.

Safety of ketorolac trometamol during pregnancy and lactation has not been established. Because NSAIDs may affect fetal circulation and reduce milk production, Kevindol is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant.

To order Kevindol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and required import documentation.

Compared with many oral NSAIDs, Kevindol offers rapid onset of action due to its injectable form, making it useful for acute severe pain where oral administration is impractical. Unlike opioid analgesics, it does not cause respiratory depression, but it shares the gastrointestinal and renal risks typical of NSAIDs.

Kevindol should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the vials from direct sunlight, moisture, and extreme temperature fluctuations. Do not freeze the product, and inspect for particulate matter before administration.

Kevindol is supplied as a sterile injection solution for intramuscular or intravenous use. Administration is performed by a qualified healthcare professional, who selects the appropriate route, dose, and infusion rate according to the patient’s clinical needs and monitoring requirements.

The most serious risks include gastrointestinal bleeding or perforation, severe renal impairment, and life‑threatening allergic reactions such as anaphylaxis. Patients with a history of ulcers, bleeding disorders, or compromised kidney function require careful assessment before receiving Kevindol.

Kevindol should be avoided in patients with active peptic ulcer disease, uncontrolled bleeding, severe renal or hepatic impairment, known hypersensitivity to ketorolac or other NSAIDs, and in those who have had a recent coronary artery bypass graft. Caution is also advised for the elderly and for patients on anticoagulants.